Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rangering i aksjer #41014
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Aksjekurs
$0.00185055
Markedsverdi
$48.29K
Endring (1 dag)
-3.55%
Endring (1 år)
30.31%
Land
GB
Handel Nuformix plc (NFX)

Kategori

Inntekter for Nuformix plc (NFX)
Inntekter i Mar 2026 TTM: $-857.89K
Ifølge Nuformix plc sine nyeste økonomiske rapporter er selskapets nåværende resultat $-857.89K. I 2024 hadde selskapet et resultat på $-4.88M, en nedgang sammenlignet med resultatet i 2023, som var $-754.56K. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Nuformix plc fra 2014 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-857.89K -3.39%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -614,967.33%
US
$-3.09B 359,735.34%
US
$-4.02B 468,046.88%
AU
$1.95B -227,477.01%
NL
- -
CH